GHR and neoplasm: In benign and malignant vascular tumors, including angiosarcoma, Kaposi’s sarcoma, hemangioendothelioma, and hemangioma, GHR is significantly upregulated in both cytoplasm and nuclei, implying that tumor cells are targets for GH action.